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Each year in the U.S., an estimated minimum of 40,000 infants are 
expected to be affected with some form of congenital heart defect (CHD), while a 
quarter of infants affected with CHD will require invasive treatment within the first 
year1. The current treatments for CHD that involve valve intervention are not 
tailored to growing children. Mechanical and biological substitute of valves 
deteriorate and accumulate calcification when implanted in very young patients2. 
In addition, children with current valve substitutes are faced with a lifetime of drug 
regimens, such as anti-coagulants, to prolong the longevity of the replacements 
and multiple surgeries for valve implantation3.  
Long-term goal:  
Our overarching aim is to create a tissue engineered pulmonary valve 
(TEPV) as a living replacement, which addresses the short comings of current 
treatments. A TEPV approach for children with CHD would create a living 
scaffold with the potential of integrating into its environment, regenerating, 
adapting, and growing in parallel with the somatic growth of the child. This will 
alleviate the need for any additional surgeries throughout their life.  
Approach: 
To achieve the goal of creating a living TEPV, we proposed combining 
non-immunogenic valve scaffolds and autologous endothelial cells obtained from 
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human adipose derived stem cells (hADSCs) by in vitro differentiation. This is 
only a first step in our larger project to seed the valve interstitium with autologous 
fibroblasts and the external surfaces with endothelial cells (ECs). The acellular 
scaffolds were obtained via decellularization of porcine pulmonary valves using a 
pressurized perfusion system. Biochemical assays and histology tests validated 
decellularization completeness and bioreactor studies confirmed valve 
hemodynamics. hADSCs were differentiated in vitro towards ECs using added 
growth factors and dynamic shear conditioning. After propagation, to optimize 
cell seeding on both surfaces of the valve scaffolds (atrial and ventricular), we 
used fibrin gel as a delivery vehicle and compared manual seeding with 3D 
bioprinting as a means of EC seeding and evaluated cell retention and viability 
using Live/Dead assays. After seeding, we exposed the seeded valves to 
physiological environments of pulmonary flow and pressures within a valve 
bioreactor for conditioning and maturation of the endothelium. 
Results  
Our data show complete pulmonary valve decellularization in our system, 
including the sinus and the ascending pulmonary artery, efficient differentiation of 
hADSCs into ECs using growth factors and shear, improved seeding using the 
3D bioprinter and adequate coverage of ECs on both surfaces of the valves after 
bioreactor conditioning. This initial success opens possibilities for complete cell 
repopulation in vitro with autologous cells before implantation. 
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CHAPTER 1: BACKGROUND INFORMATION 
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1: ANATOMY AND PHYSIOLOGY 
1.1: HEART AND CIRCULATION 
A normal healthy heart is a muscular organ that sits inside the chest, and 
is composed of four valves, two atriums and two ventricles. The purpose of the 
heart is twofold, to push oxygenated blood to the extremities and to push 
deoxygenated blood into the lungs. 
 




A normal heart’s anatomy is shown in FIGURE 14, where the blue shaded 
regions show the path of deoxygenated blood (blue arrow) and the red shaded 
region shows the path of oxygenated blood (red arrow). The heart is a large 
pump which expels bursts of blood to the circulatory system. The heart is 
compartmentalized as the right and left side, where an atrium and a ventricle 
reside. The right and left side are separated by a septum which allows blood that 
is (left) oxygenated or (right) deoxygenated to be separate. The atria are 
considered primer pumps2 for the ventricles, specifically holding residual blood 
within while the ventricle is either contracting or relaxing. The ventricles are 
considered the main pumps due to the larger volume of blood they can hold, and 
the force which the right or left ventricle propels blood into the lungs or the rest of 
the body, respectively.  
Blood circulates throughout the heart following the cardiac cycle, which 
consists of a period of relaxation/contraction, diastole/systole. During diastole, 
the heart fills with blood followed by systole, where blood moves through its 
respective path. In addition, during the cardiac cycle pressure gradients occur as 




The deoxygenated blood from the trunk and lower extremities come into 
the right side of the heart into the right atrium through the inferior vena cava, 
while the deoxygenated blood from the head and upper extremities comes in 
from the superior vena cava (FIGURE 2: A5).  
FIGURE 2: Blood flow patterns. A) Circulation within the heart. B) Path of blood 
circulation throughout the body and locations where gas exchange occurs. Images from 






The atrioventricular valves (A-V valves, shown in FIGURE 36 as the 
tricuspid and mitral valve) are located between the atria and the ventricle, 
prevent backflow from the ventricle; while the semilunar valves (Shown in 
FIGURE 3, as the aortic and pulmonary valves) prevent back flow from the aortic 
and pulmonary arteries into the ventricles during diastole. Both right and left 
heart pump in parallel where the ventricles fill passively, then the atrium then 
contract near the end of ventricular diastole, any residual blood in the atrium is 
forced into the ventricle during the contraction and the A-V valves close. The 
closure of the valves is due to increasing pressure in the ventricles as they start 
to contract. As the ventricles contract, pressure within reaches a threshold which 
opens the semilunar valves. As blood is ejected through the semilunar valves, 
FIGURE 3: Cross-sectional image of heart, all heart valves are visible. Image by OpenStax, 




the pressure within the ventricle is relieved and the semilunar valves and the A-V 
valves open to start the cycle again7. Finally, the blood from both sides of the 
heart follow their respective paths to meet at locations where there is gas 
exchange such as capillaries, kidneys, gastrointestinal tract, and the lungs 
(FIGURE 2: B5). 
Valve closures occur passively according to the pressure gradient over the 
valve. Closure of the valve occurs when the backward pressure gradient causes 
the blood to flow in a backward direction; opening of the valves occurs when the 
forward pressure gradient causes the blood to flow in the forward direction.  
The focus of the rest of the literature will be on the pulmonary valve which 
is paramount in the circulation of the blood as it is the valve which leads to the 
conduit for the lungs to oxygenate the blood.  
 
1.1.1: FETAL HEART DEVELOPMENT AND FETO-NATAL  
CARDIOVASCULAR TRANSITION 
Many changes can arise during the development of the heart; thus, it is 
important to understand its development from gestation to birth. The heart arises 
from the mesoderm, one of the three primary germ layers, and is the first 




During embryonic development (around day 21 or 22 of fertilization)8, the 
heart bulge is seen on the anterior surface of the embryo, known as the 
cardiogenic area (Top left, FIGURE 4). Receiving signals from the endoderm, the 
cardiogenic area forms two strands called the cardiogenic cords. As the cords 
develop, the lumen develops with in. At this point, they are referred to as 
endocardial tubes, at 20 days (FIGURE 4). The endocardial tubes fuse together 
to form a primitive heart tube (21 days, FIGURE 4), where five distinct regions 
are formed, from head to tail: truncus arteriosus, bulbus cordis, primitive 
ventricle, primitive atrium, and sinus venosus. At this point all venous blood flows 
into the sinus venosus, and contractions propel the blood from tail to head, or 
FIGURE 4: Progression of Embryonic Heart Development. Image by: OpenStax, Houston, 
Texas, 2020– Anatomy & Physiology 
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from sinus venosus to truncus arteriosus. Further progression occurs where the 
chambers of the heart are developed (Bottom row, FIGURE 4). 
 
Information from the National Health Services in the United Kingdom 
indicates the fetal heart is fully developed at 10 weeks9. Even though the organ 
in fully formed, the blood circulation is not yet like an adult, depicted in FIGURE 
5. Oxygenated blood and nutrients flow into the unborn baby from the umbilical 
cord. The enriched blood flows through the umbilical vein towards the fetus’s liver 
and moves through the ductus venosus, a shunt. As the blood flows through the 
shunt, some blood stays in the liver while most flows through a large vessel, the 
inferior vena cava, into the right atrium of the heart. Once the enriched blood is in 
the heart, most of it flows through the foramen ovale, another shunt, into the left 
FIGURE 5: Fetal Circulation. Image by Stanford Children’s Health, 2020. 
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atrium. From the left atrium, the blood flows into the left ventricle and then it is 
pumped through the ascending aorta where the blood is dispersed to the brain, 
the heart muscle, and to the lower body. In contrast, the blood that returns from 
the fetal body, containing carbon dioxide and waste products, enters the right 
atrium and flows into the right ventricle. As an adult, the blood at this stage would 
go to the lungs, but instead the fetal venous blood bypasses the lungs and flows 
through the ductus arteriosus into the descending aorta, which connects to the 
umbilical vein. Carbon dioxide and waste products in the blood are exchanged 
for oxygen and nutrient enriched blood through the placenta, where the cycle 
begins again.  
At the point of birth, the newborn goes through drastic changes as they 
take their first breath. As the newborn’s umbilical cord is clamped, seizing the 
avenue of blood supplied by their mother, the lungs expand, and the ductus 
arteriosus, ductus venosus, and foramen ovale close. At this point, the infants 
blood circulation is the same as an adult. Further discussed, will be the anatomy 
of the heart valve anatomy and physiology.  
 
1.2: HEART VALVE ANATOMY AND PHYSIOLOGY 
1.2.1: STRUCTURE 
For many years, heart valves have been assumed to be passive 
participants during the cardiac cycle. Many believed that only due to changes in 
11 
 
transvalvular pressure and myocardial reaction, heart valves opened and 
closed10. The heart has four valves, grouped into the A-V valves and semilunar 
valves. The focus of this dissertation are semilunar valves which need to be 
analyzed and understood further for the advancement of this dissertation.  The 
aortic valve and pulmonary valves have many commonalities due to their similar 
roles in the heart, especially their placement which induces pressure on both. 
The Center for Disease Control states that valvular heart disease deaths are 
more commonly attributed to aortic valve disease11, thus it has been studied 
more than the pulmonary valve. The aortic valve is consistently exposed to 
increased pressures in comparison to the pulmonary valve. The pulmonary valve 
is situated between the right outflow tract of the heart which leads to the lungs, 
and the right ventricle12 and is comparable in design to the aortic valve.  One of 





In FIGURE 613 the macro-structure of the pulmonary valve is depicted, as 
a transactional view  of the pulmonary artery in the middle the pulmonary valve at 
the top of the image and an open view at the bottom of the figure. In the 
transactional view of FIGURE 6, the pulmonary valve can be seen in its 
anatomical placement, where the top is the pulmonary artery which then leads to 
the lungs and the bottom is the right ventricle. The point which the three leaflets 
meet is called the nodule. Each leaflet is a thin membrane and is referred to their 
anatomical position in the heart, which are the anterior, left, and right leaflet. 
FIGURE 6: Illustration of the pulmonary valve. Top: Cross Sectional view of the valve, with the 
pulmonary artery above and right ventricle below. Bottom: Pulmonary valve transected between 
the right and left leaflet. Image adapted by Margarita Bruce from Shatarat, A. “Two 
atrioventricular valves Two semilunar valves.” 200817. 
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Behind each leaflet is their respective sinus, and the point which they meet is 
called the commissure; one commissure connects the right leaflet with the 
anterior leaflet, another connects the anterior leaflet with the left leaflet, and 
finally the last one connects the left leaflet with the right leaflet. At the top of each 
sinus, there is a circular ring called the sinotubular junction which is composed of 
a muscular ring that defines where the pulmonary valve sits inside the artery.  In 
comparison to the aortic valve, the pulmonary leaflets are thinner and the noduli 
are smaller than their valvular counterpart12. The pulmonary leaftlets consist of 
the hinge, the belly, and the coapting surface and the lanulla with the noduli of 
Aranti12.  
 
Microscopically, the pulmonary leaflets have the same three regions as 
the aortic leaflets, which are the fibrosa (superior layer close to the pulmonary 
artery), spongiosa, and the ventricularis (FIGURE 714). Unlike the aorta, these 
layers are often thinner, especially the center layer of the spongiosa15. Under the 
ventricular endothelium of the pulmonary valve is the lamina ventricularis which 
FIGURE 7: Pulmonary valve with layers identified as (TOP) fibrosa, (MIDDLE) spongiosa, and 




consists of a tight network of retricular fibers with sparce collagenous and elastic 
fibers. Following the ventricular lamina, present is the lamina radialis which is 
composed of radial oriented collagenous and elastic fibers with space reticular 
fibers. This layer is then proceeding into the endocardium and the 
subendocardial layer of the ventricle12. Furthermore, the microscopic 
environment of the pulmonary valve is dictated by the cellular components of 
each region of the valve, such as endothelial cells and interstitial cells.  
 
1.2.2: CELLULAR ANATOMY 
1.2.2.1: VALVULAR ENDOTHELIAL CELLS 
As per Chester, A.H. et al 10 heart valves have initially been referred to as 
passive structures, but with much further investigation the living components of 
the valves have led to the reconsideration of the valves dynamic role. Cellular 
components, such as the endothelial cells, have demonstrated the dynamic 
constituents of the heart valves. The endothelium of the leaflets of valves have 
shown a remarkable manner of adapting to shear stress, bending forces, loading 
forces, and strain10,16. Unlike their vascular counter parts, valvular endothelial 
cells are aligned perpendicular to flow patterns, which is observed regardless of 
substrate structure10,17. In regards to vascular endothelial cells, 
mechanotransduction pathways such as Rho-kinase, phosphatidylinositol-3-
kinase and calpain are induced by laminar flow; where as such pathways are not 
required for cytoskeletal reorganization in valvular endothelial cells10. In addition, 
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valvular endothelial cells proliferation is higher than their vascular counterparts10. 
The differences between the vascular and valvular endothelial cells demonstrate 
a difference in roles the endothelium has regarding their environmental site. 
Although it is believed that the endothelial cells both have similar physiological 
roles, valvular endothelial do not act like their vascular counterparts.  
Valvular endothelial cells express von Willebrand Factor (vWF) and tissue 
factor in aid to regulate coagulation16,17, thus being non-thrombogenic unless 
inflammatory cytokines and/or other related factors analogous to injury are 
detected. In addition, due to the constant repeated flow changes, endothelial 
denudation is resisted thus coagulative factors tend to not be released as easily 
as their vascular kin. In addition, endothelial cells interpret and respond to agents 
in blood, which could be coagulative factors, nutrients, and other molecular 
stimulants. Although valvular endothelial cells have been determined to have 
diffusion limits 250µm (within the range of small blood vessels) in hypoxic 
environments angiogenesis would occur, but the valve leaflets little to no blood 
vessels inside16-18. Another duty of endothelial cells is regulation of underlying 
cells. For the valvular associated cells, the underlying cells are valvular interstitial 
cells (VICs) which are more fibroblastic in nature16,19. Valvular endothelial cells 





In Fajardo, et al’s21 review of the complex behavior of endothelial cells, they 
follow afore mentioned behaviors such as interpretation of molecules and/or 
signals from surrounding their environment, angiogenesis, tone regulation, and 
special metabolic functions. It is important to consider the characterization of 
endothelial cells properly, as they not only need to express proteins that identify 
the cell as endothelial, but also function as one (FIGURE 8). In this regard, three 
proteins are identified as endothelial cell characteristics, as well as one metabolic 
FIGURE 8: Depiction of complexity of endothelium, as per processes and protein 
expressions, such as (A) CD31 (also referred to as PECAM-1), (B) von Willebrand Factor 
(vWF), and (C) endothelial nitric oxide synthase (eNOS). Adapted by Margarita Bruce from 
“Special Report: The Complexity of Endothelial Cells: A review” by Fajardo, et al. 1989 24. 
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function which are CD31, vWF, eNOS, and uptake of acetylated-low density 
lipoproteins, respectively21.  
CD31, also referred to as PECAM-1, is a protein that helps identify cell to cell 
communication between endothelial cells (Fig 8, A); vWF is a protein stored 
within the cell cytoplasm and will be released if injury occurs to the cell thus 
initiating a signal cascade of injury to the rest of the cells (Fig 8, B); and finally, 
endothelial nitric oxide synthase (eNOS), an enzyme that reacts to shear stress 
that then signals the underlying basal lamina to conduct tone regulation to cells 
underneath of the endothelium layer (Fig 8, C)22.  Endothelial cell’s complex 
functions lead us to further examine their influence on other cells, such as 
smooth muscle cells for vascular endothelium and valvular interstitial cells for 
valvular endothelium.  
 
1.2.2.2: VALVULAR INTERSTITIAL CELLS 
Valvular interstitial cells (VICs) are a dynamic population of at least two 
distinct cells, smooth muscle cells with α-smooth-actin expression, and 
fibroblasts10,12. Interstitial cells can contract and remodel, creating an active 
population of cells which respond to various changes in their environment16,  
such as valvular endothelial cells19. Unlike smooth muscle cells, VICs are highly 
dynamic producers of protein and glycoaminoglycans19. 
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VICs are highly susceptible to changes, due to their own elevated dynamic 
and dependency on valvular endothelial cells23, to abnormal mechanics from 
their environment. To elaborate, any anomaly of the valvular environment affects 
valvular endothelial cells, in turn, due to the endothelial cells’ function, VICs are 
highly affected. Thus, the consideration of maintaining a normal valvular 
environment is paramount to avoid any cascade of abnormalities to deter any 
valve to become pathological. Cases of valve pathology are seen in congenital 
heart defects where the valvular environment is disrupted due to a defect, thus 
the need to mitigate the defects to reduce ultimate failure of the heart.  
 
2: PATHOLOGY OF CONGENITAL HEART DEFECTS 
2.1: STATISTICS OF DISEASE 
Cardiovascular disease (CVD) is the prime cause of death globally24, 
furthermore taking an estimated 17.9 million lives each year25 worldwide. It is 
speculated that by 2030, 43.9% of the United States population will have some 
form of CVD26. Under the umbrella of CVD, more than five millions of Americans 
are diagnosed with heart valve disease (HVD) each year27,28,. Although most of 
the population that suffers from HVD are the elderly, the population of growing 
children cannot receive the same treatment as their older counterparts. In the 
U.S., hospital costs for individuals with cardiovascular defects in 2013 were 
about $6.1 billion, where critical congenital heart defect associated 
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hospitalizations had the highest mean and median cost of the birth defect 
categories considered ($79,011 and $29,886, respectively)29,30. 
Events which may lead children to have heart valve defects at birth, 
referred to as congenital heart defects (CHD), lead to extensive surgeries 
throughout the infant’s life.  The American Heart Association estimates that out of 
1,000 births at least eight babies will have some sort of CHD in the United 
States31,32.  
 
2.2: CRITICAL HEART DEFECTS 
About one in every four babies born with a heart defect has a critical CHD 
(CCHD) , identified as heart defects that lead to low levels of oxygen in a newborn,  
and will have an invasive intervention with in their first year of life30. The cost of 
identifying a newborn with critical CHD has been estimated at $20,862 per 
newborn detected12 and hospitalizations with critical CHD account for 26.7% of all 
costs for CHD hospitalization29, where pediatric hospitalizations with CHDs 
accounted for approximately $5.6 billion in hospital costs, representing 15.1% of 
costs for all pediatric hospitalizations in 20094. 
CHD can be diagnosed during pregnancy using a special type of ultrasound, 
called a fetal echocardiogram, which creates pictures of the heart of the developing 
baby. If the defects are not able to be identified during the pregnancy, they can be 
identified at birth or as the child ages. Low levels of oxygen detected with pulse 
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oximetry are the primary identification of a potential CCHD, such as pulmonary 
atresia (FIGURE 9: A4), hypoplastic left heart syndrome (FIGURE 9: B30), 





FIGURE 9: Examples of Congenital Heart Defects. A. Pulmonary Atresia defect- the 
pulmonary valve does not form; box identifies the defect. B. Hypoplastic Left Heart 
Syndrome- The left side of heart does not form correctly; box identifies the defect. Potential 
structures effected are the left ventricle, the mitral valves, the aortic valve, the ascending 
aorta, and the atrial septum. C. Coarctation of the Aorta- The aorta is narrower than usual. 
D. Tetralogy of Fallot- Birth defect that affects normal blood flow through the heart, usually 
made up of four defects. 1) A ventricular septal defect, 2) Narrowing of pulmonary valve and 
main pulmonary artery, also known as pulmonary stenosis. 3) Aortic valve is enlarged and 
due to the ventricular septal defect, opens from both ventricles. 4) Muscular wall of lower right 
ventricle is thicker than normal, called ventricular hypertrophy. Box identifies the defect. 
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2.2.1: MORPHOLOGY OF PATHOLOGY 
An example a CCHD is hypoplastic left heart syndrome (FIGURE 9: B30), 
which is the underdevelopment of the left side of the heart, where 1,025 babies 
each year suffer from this CHD in the United States35. Due to the 
underdevelopment in the heart it leads to interrupted blood flow in the heart, 
mixing the oxygenated and deoxygenated blood, resulting in low levels of oxygen 
of the infant. During the first few days of life with hypoplastic left heart syndrome, 
the baby’s patent ductus arteriosus and patent foramen ovale may remain open 
so the blood can continue to be oxygenated. At the point in which these 
alternative routes close, the infants blood oxygen will rapidly decrease, and 
surgical intervention is imminent.  Even though infants receive surgeries to 
alleviate the condition, it is a lifelong debilitation. Children who undergo surgeries 
for their hypoplastic left heart syndrome are not cured of the defect. Infants who 
are affected by the defect may have life-long complications which would increase 
with the complexity of the CHD. Ultimately, if repeated surgeries are needed 
and/or the heart weakens, a heart transplant may be the only viable alternative 
for the correction of this syndrome36. Coarctation of the aorta (FIGURE 9: C33) is 
another CHD that is considered critical, where 4 of 10,000 babies are affected35, 
which consists of the narrowing of the aorta. If the narrowed aorta is severe 
enough and not diagnosed, the baby may have serious problems and may need 
surgical intervention after birth33.  
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Another CCHD that requires surgery is the Tetralogy of Fallot due to its 
complex defects, CDC estimates that each year 1,660 infants are born in the 
United States37. In the Tetralogy of Fallot (FIGURE 9: D34) there are four defects 
in the heart which are: 1) A ventricular septal defect, 2) Narrowing of pulmonary 
valve and main pulmonary artery, also known as pulmonary stenosis, 3) 
Enlarged aortic valve and due to the ventricular septal defect, opens from both 
ventricles, and 4) Abnormal thickness of muscular wall of lower right ventricle, 
called ventricular hypertrophy15. Surgery after birth is the treatment for this CHD 
where surgeons widen or replace the pulmonary valve and enlarge the pathway 
of the pulmonary artery. In addition, a patch will be placed to address the 
ventricular septal defect. After these interventions occur, the abnormal thickness 
of the muscular wall and enlargement of the aortic valve are regulated as there is 
less stress in the heart due to the corrections of the defects.  
Finally, pulmonary atresia (FIGURE 9: A4) is a CCHD which there is the lack 
of development of the pulmonary valve38. The underdevelopment of or absence 
of the pulmonary valve disrupts the blood flow of the heart, especially before it is 
oxygenated in the lungs. Due to the lack of formation of the pulmonary valve, an 
infant’s blood must take other routes to get oxygenated, such as the foramen 
ovale4, which is normally closed at when the infant is first born. Pulmonary 
atresia may present itself in many variants but is commonly characterized by 
whether there is a ventricular septum defect or intact ventricular septum. It is 
certain the pediatric patient will need a corrective surgery to treat the pulmonary 
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atresia due to their inability to oxygenate their blood in a normal manner, leaving 
the infant with lower oxygen levels than are considered healthy. In a 2019 study, 
using data from 2010-2014 in the National Birth Defects Prevention Network, it 
was estimated that about 550 babies each year in the United States were born 
with pulmonary atresia35. 
 
2.2.1.1: MORPHOLOGY OF PATHOLOGY INVOLVING PULMONARY VALVE 
ABNORMALITIES 
A majority of diagnosed congenital heart defects, 85%, are considered 
multifactorial in origin, such as epigenic, environmental, biomechanical, and 
hemodynamic factors, to list a few39. Abnormalities to fetal heart development, 
explored by Groot et al.39 via different animal models but not yet understood fully, 
can then cause an irregular developments of valves of the heart. Such 
abnormalities could affect the PV, which could lead to pulmonary atresia in an 
infant. In cases of pulmonary atresia, 75% of instances the PV is membranous 
while in the remainder of the situations, the PV is muscular. Chubb, et al.38 
recognized two groups when the PV is membranous: Lower pressure in the right 
ventricle, which is seen in severe tricuspid regurgitation, and prominent 
commissural ridges that meet at the center of the thickened PV, and higher 
pressure in the right ventricle with less prominent commissural ridges and 
smooth thin portions of the PV38. Specifically in pulmonary atresia, the right 
ventricle could be effected to either be hypoplastic and hypertrophied38,40 or the 
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right ventricle could be huge dilated, and a thin walled cavity38. What is 
consistently seen is a disarrayed myocardium and increased fibrosis38,40.  
CCHDs which affect the right ventricular outflow tract (RVOT), such as the 
Tetralogy of Fallot, inadvertently have several variations to their morphology. 
One variation, particular to the Tetralogy of Fallot, would be the override of the 
aortic valve over the ventricular septum defect41. Another observation made by 
Khan, et al. 41 is where the orifice and origin of the coronary arteries, which is 
abnormal in nature. Coronary arteries present in CCHDs could cross the RVOT 
and in these cases when surgical intervention occurs to rectify defects, the 
identification of the coronary abnormalities is paramount for the success or 
management of the CCHD. Pulmonary valve abnormality, such as pulmonary 
stenosis or pulmonary atresia, leads to the RVOT obstruction thus leading to 
increased pressure in the right ventricle. As the degree of stenosis increases the 
right systolic pressure increases, approximately as a squared function42, in order 
to maintain the cardiac output. As a neonatal develops their response to overload 
of the right ventricle is compensated by an increased number of capillaries, which 
provides the capacity to produce extremely high systolic ventricular pressures42. 
Stroke volume in neonates is usually maintained by the hypertrophied muscle, 
although sustained elevated pressure for a period of time, cardiac failure could 
occur if the ventricle dilated42, but often cardiac output is maintained. These 




2.2.2: HISTOLOGY OF PATHOLOGY 
 Even though most CCHDs have macroscopic deformities that can be 
detected once the heart is looked at, they create alternative morphologies of the 
heart as it tries to compensate for the defect. These alternative morphologies are 
from the macroscopic level to the microscopic level. Research teams, such as 
Groot, et al40,43 and Chowdhury, et al44,45 have analyzed the histopathology of 
various heart defects at different stages of a fetus’s development or of a CCHD. 
 FIGURE 10 shows multiple sections from a 20-week fetus, the fetus has 
pulmonary atresia without a ventricular septum, published by Groot, el al40 
(Progress in Pediatric Cardiology, 2010). In this case, after birth, doctors would 
have to surgically correct the pulmonary valve before the foramen ovale were to 
close. Also, due to the pulmonary deformity, there will higher pressure in the right 
ventricle to accommodate for the deformity. In FIGURE 10 A, B, and C there is 
coronary pathology with intimal thickening and severe adventitial fibrosis in the 
subepicardial (SEP) coronary arteries (CA). In FIGURE 10 D the coronary 
arteries are severely affected, in the manner of which they are not there. Further 
sections were analyzed by Groot, et al43 (Progress in Pediatric Cardiology, 2001) 
where ventriculo coronary arterial communications (VCACs) was one of their 
main focuses. In FIGURE 10 E and F, the right ventricular wall was of a 20-week 
fetus was stained and the intimal thickening of the subepicardial artery was 
noted. In addition, in FIGURE 10 F, a more distal section, showed the 
abnormality of coronary arteries, where one of them is completely blocked by 
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intimal thickening (arrow). FIGURE 10 G and H shows the same specimen as E 
and F, with detail view of the wall of the VCAC, which shows no muscular media 
(M, in FIGURE 10 G) and the internal elastic lamina of the VCAC on the border 
of the intima and destructed media. Demarcation of the side of the ventricular 
lumen is shown with an arrow in FIGURE 10 H.  
 FIGURE 10 I shows the hypoplastic right ventricle of a 5.5-week infant 
with pulmonary atresia. In this case, there is extensive endocardial fibroelastosis 
(EFE) lining the right ventricle extending to the fibrous tissue that encircles the 
hypertrophied cardiomyocytes (M), which is described as a pathological 
morphology of CCHDs. Finally, Groot, et al’s group continue to study the 
pathologies of CCHDs throughout the development of an embryo. The availability 
of such human specimens are highly regulated and in limited supply, thus their 
search for an animal model for study. FIGURE 10 J is an example of an animal 
model, a chick embryo which was manipulated to inhibit epicardial transformation 
and coronary vasculature formation. The histological sections show the right 







FIGURE 10: Histology from 20-week fetus with Pulmonary Atresia with Intact Ventricular 
Septum (A-D) 40. Sections of right ventricular (RV) wall of a 20-week human fetus with 
pulmonary atresia and ventriculo coronary arterial communications (E-H)43. Section of the wall 
of a hypoplastic right ventricle of a 5.5-week infant with pulmonary atresia, and myocardial 
sinusoids (I)43. Section through the right ventricular apex of a HH35 chick embryo that was 
manipulated to inhibit epicardial transformation and coronary vascular formation (J) 43.  
Images taken by Gittenberger-de Groot, et al. Progress in Pediatric Cardiology 29 (2010) 3–9 
40 and Gittenberger-de Groot, et al. Progress in Pediatric Cardiology 13, 157-164 (2001) 43. 
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 Other histological analysis of the pathology of CCHDs have been 
published by Chowdhury, et al. in two articles “Histopathology of the right 
ventricular outflow tract and the relation to hemodynamics in patients with 
repaired tetralogy of Fallot” (J Thorac Cardiovasc Surg, 2019)44 and “Central 
pulmonary artery histopathology in patients with cyanotic congenital heart 
diseases” (Ann Thorac Surg, 2009)45. FIGURE 11 encapsulates the histology 
in these articles. For FIGURE 11 A and C, these were sections taken from a 
patient with Tetralogy of Fallot at the point of the Right Ventricular Outflow 
Tract. The Hematoxylin and Eosin (H&E) stained sections (FIGURE 11 A and 
C) the asterisk indicates myocyte hypertrophy and large hyperchromatic 
nuclei (FIGURE 11, C). The patient’s heart has accommodated the abnormal 
hemodynamics of the defect, it has affected the cells within the heart and the 
RVOT. The other images (FIGURE 11 B and D) show perivascular fibrosis 
(indicated with an asterisk) after using Masson’s Trichrome Stain. In this 
section is the amount of blue collagen fibers is what accounts for the fibrosis, 
as it is in disarray and thicker than what normally would be seen in the RVOT. 
Particularly in the FIGURE 11 E and F, Chowdhury, et al. focused on patients 
with cyanotic CHDs, thus patients who were not able to keep their oxygen 
levels up to par as their body needed and having episodes of oxygen 
deprivation. In FIGURE 11 E, the section shows a pulmonary artery biopsy 
form a patient with Tetralogy of Fallot which shows a disorganized media with 
a loss of smooth muscle cells, and varying grades of mucoid ground 
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substance accumulation. Finally FIGURE 11 F is of a patient’s biopsy of their 
pulmonary artery undergoing superior cavopulmonary connection, which 
shows significant medial destructions, changes in smooth muscle cell 
orientation, and intimal thickening. Ultimately the cavopulmonary connection 
is coupled with other corrections and surgeries, but it alleviates the patients 
cyanotic state even though there are still implications of continuous 
abnormalities in the patient’s heart.  
 All these depictions of histology show that there is a need for ultimate 
replacement of vital parts of the heart, so a child does not have continuous 
invasive medical treatments, nor does the child ultimately have to have a 
heart replacement due to the fundamental damages the defects cause in their 






FIGURE 11: Histology of the Right Ventricular Outflow Tract biopsy of patients with Tetralogy 
of Fallot (A-D)44. Histology section from pulmonary artery biopsy of a patient with tetralogy of 
Fallot shows disorganized media with loss of smooth muscle nuclei and varying grades of 
mucoid ground substance accumulation(E)45. Histology section from pulmonary artery biopsy 
of a patient undergoing superior cavopulmonary connection shows significant medial 
destruction, changes in smooth muscle orientation and intimal thickening(F)45. Images taken 
from Chowdhury, U.K., et al. J Thorac Cardiovasc Surg 158, 1173-1183 e1175 (2019)44 and 
Chowdhury, U.K., et al. Ann Thorac Surg 87, 589-596, 596 e581-583 (2009)45. 
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2.2.3: OTHER CHANGES DUE TO CHD 
 Due to multiple surgeries to correct or alleviate symptoms of CCHDs, 
children will continue to need medical attention for the rest of their lives. Also, 
surgeries may occur more than once, but if they are done to alleviate symptoms 
other problems may occur45 as seen in FIGURE 11 F. As the child who had or 
continuous to have defects in their heart, they exercise capacity may be limited47. 
If a child had a CCHD that is not common or is more complex to treat, the child 
may have developmental delays or other learning difficulties47. Furthermore, it is 
imperative to find solutions for children with CCHDs and their families, as the 
burden of continuous medical treatment may have social and financial impacts 
on all involved47. 
 
2.2.4: CURRENT TREATMENTS 
Treatments for CHD, such as tetralogy of Fallot, include the replacement 
or alteration of the pulmonary valve (PV), to ensure alleviation of symptoms. 
Follow up treatments occur as the child ages due to the lack of adaptability of the 
procedures, leading to a cost of $40,385 per life-year gained (2011 US dollars) 
until the age of 2048. Current models for replacements, such as mechanical and 
biological, have limited life spans due to bleeding risk49 and degradation and/or 
calcification50, respectively and do not grow with the patient.  
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Current treatments for CHD involving surgery or replacement of the PV do not 
consider the children’s change in immunity nor size. An example of CHD is a 
child born with a defect in the RVOT, which is a functional unit in the heart that is 
located between the supraventricular crest and the PV, such defects include 
tetralogy of Fallot and pulmonary atresia51,52. The function of the RVOT is to 
carry blood from the right ventricle to the lungs, making the PV a paramount 
piece in the process. At the time of diagnosis of defect in the RVOT invasive 
surgery is imminent for the child, but current PV replacement options of 
xenografts, allografts, and mechanical devices will typically fail and require 
another surgery53.  
Palliative procedures are considered as an avenue of treatment for most 
CCHD cases, as symptoms are the first to be addressed i.e., cyanosis in an 
infant. If the palliative procedure is invasive, the surgeon may need to wait to 
intervene again54. Such cases can be to address the defect of the PV and other 
defects that cause the heart not to distribute non-oxygenated blood and 
oxygenated blood in an efficient manner may alleviate symptoms until the next 
surgery. Cases have been studied to see whether palliative procedures should 
be the first step to management of the CCHDs55, which turns out to be the 
manner in most cases but depends on the complexity of the defect. In 
Hypoplastic Left Heart Syndrome, a severe CCHD where surgery is imminent for 
the infant’s survival. In Hypoplastic Left Syndrome, doctors usually need at least 
three surgeries to ultimately correct the underdevelopment of the infant’s heart.  
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One of these three surgeries is the Fontan procedure which creates an 
alternative pathway for deoxygenated blood to go from the superior vena cava 
and the inferior vena cava to the pulmonary artery56. There are continuous 
studies of surgical management of various CHDs such as Tetralogy of Fallot57,58 
where the claim tends to be that if a corrective surgery is possible then it should 
be done, while in more complex cases palliative procedures should be 
considered. In addition, there are cases where reconstruction needs to be 
considered as it may have been a result of either a surgery or the CHD, one of 
which is the reconstruction of occluded pulmonary arteries59. After the procedure, 
after 4 years (median of the study) patients returned and received a cardiac 
catheterization59.  Other follow-ups are seen after care of CCHDs or palliative 
care, one of which is pulmonary regurgitation after Tetralogy of Fallot repair60. If 
any degree of pulmonary hypertension or pulmonary stenosis occurs, pulmonary 
regurgitation is enhanced and right ventricular dilatation is accelerated60. 
Ultimately the procedures to treat CCHD are adequate for now, but there is a 
need to alleviate their problematic recurrence of treatment for the same defect or 
for some other problem that arose from the procedure.  
 
2.2.4.1: PULMONARY VALVE REPLACEMENTS 
 If a CCHD affect the pulmonary valve and no repair nor reconstruction can 
be done, alternatives are considered for pulmonary valve replacements. Most 
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commonly used replacements are mechanical prosthetic, or bioprosthetic 
valves61. Mechanical prosthesis have thromboembolic risk and lifetime of need 
for anticoagulants26, while xenografts and allograft used for right ventricular 
outflow tract reconstruction in children and young adults often degenerate and 
fail52.  
Approximately 85,00 substitute valves are implanted in the United States 
each year, where half are mechanical valves and have are bioprosthetic2. Within 
15 years following implantation, approximately 50% of porcine aortic valves 
suffer tissue failure, thusly although bioprosthetic valves are more attractive for 
valve replacements there is a high rate of failure due to structural dysfunction 
due to deterioration62-67. Degradation of biological grafts often begins via the 
process in which the valve is made, as chemical, mechanical, and morphological 
changes occur during manufacturing61. In addition, during fixation of porcine 
aortic valve or bovine pericardial tissue leads to destruction of residing cells 
which limits their own function to remodel after placement61, and the fixation 
locks the collagenous tissue neglecting its function for elasticity in the valve61. 





Moreover, due to the children’s high immunological competence29, while 
surgical approaches to reconstruct valves making use of auto or commercial 
available pericardium to augment defective cusps or fabricate mono cusps26 
have variable results, as it depends on30,68 but most often fibrosis occurs69. 
  
2.2.4.2: LIFE AFTER CURRENT TREATMENTS 
 Children with CCHDs that are not relatively complex, may lead normal 
lives – if their exercise is limited, and no hypertension nor stenosis occurs47. 
Other patients may lead to have more surgeries to ultimately correct their 
defects, but with repeated surgeries their hearts might weaken, which may lead 
to congestive heart failure. In cases where the child develops congestive heart 
failure, a heart transplant is required to save the child’s life70. Now the patient 
population that needed to have a PV replacement will have their own plethora of 
challenges, such as a mechanical heart valve will lead the child to take a lifetime 
FIGURE 12: Pictorial hypothetical model for calcification of bioprosthetic tissue. Adapted by 
Margarita Bruce from Schoen, FJ and Levy, RJ. Ann Thorac Surg 79 (2005). 
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of anticoagulants and potential recurrence of PV replacement due to the lack of 
adaptability of the replaced valve with the growth of the child61. Similar 
circumstances of failure can occur with allografts or xenograft valve 
replacements due structural degeneration61. 
 
2.3: GAP 
Mechanical prosthesis have thromboembolic risk and lifetime of need for 
anticoagulants26, while xenografts and allograft used for right ventricular outflow 
tract reconstruction in children and young adults often degenerate and fail52. Due 
to concerns of the lack of options for children with CHD tissue engineered 
constructs continue to be considered if it prevails it can also another approach for 
other patients. A tissue engineered pulmonary valve (TEPV) addresses the short 
comings of the current methods of valve replacement by creating a living PV. 
 
3: SOLUTION: HEART VALVE TISSUE ENGINEERING 
3.1 TISSUE ENGINEERING PARADIGM 
As per the notion of tissue engineering, the use of a scaffold, such as a 
decellularized porcine pulmonary valve, and autologous cells creates a living 
replacement for the organ. The identification of the scaffold, such as a porcine 
pulmonary valve, is essential to be comparable to its fresh counterpart. In 
addition, the decellularization process removes the potentially immune-rejective 
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components, while keeping the structure of the organ. Following the preparation 
of the scaffold, autologous cells are embedded into the scaffold and the 
combined construct into a conditioning environment (FIGURE 13). 
 
 The use of a natural scaffold may retain cues which could signal the 
patient’s own cells to repopulate the scaffold. In addition, the construct might 
adapt to become the patient’s pulmonary valves and regenerate as the child 
grows. The regenerative properties of this method could ultimately eliminate the 
gap of treatment and the path the way to tailor treatments to the patients. 
 
3.1.1: CELL SOURCE 
Concurrently, with the notion of the use of autologous cells the use of human 
adipose derived stem cells (hADSCs) as a cell source which are considered for 
FIGURE 13: Tissue engineering paradigm 
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the cell population in the tissue construct due to their various advantages of 
availability, isolation protocols, and multipotency. The readily availability of 
human adipose derived stem cells71,72 and “ability to isolate a consistently 
homogeneous population of undifferentiated adult stem cells from adipose 
tissue”71 as expressed by Aust, et al makes the source highly desirable. The cells 
are also multipotent73,74 as their differentiation properties allow the cells to follow 
the path of endothelial cells and smooth muscle cell. The endothelial cell 
differentiation, hADSCs are said to have a common progenitor that leads this 
differentiation21. The importance of differentiation of hADSCs into endothelial 
cells leads to the lining of the scaffold, which will a may ease coagulation and 
anticoagulation21 reaction, inflammation, and immune response75.heart 
 
3.1.2: SCAFFOLDS 
The use of acellular xenografts as a scaffold follows the tissue engineering 
paradigm (TEP). Once the constituents of the TEP of cell and bioreactor are 
established, the scaffold is a decellularized material (heart valve, for the purpose 
of this project). The decellularization process is followed to remove any antigenic 
material that would cause a response from the host76. In this regard, the 
decellularized graft is in essence material that does not cause a response from 
the host but also a structure which autologous cells will attach and proliferate due 
to the “natural environment”. Therefore an acellular xenograft has the 
macrostructure for the intended physical position and environment, 
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microstructure to induce cell attachment and migration, and molecular structure 
in which it has the ability to release molecules to induce specific cell response77.  
While autologous cells are isolated and cultured, the acellular scaffold can be 
created and with combination of the cells and scaffold  a chimeric structure is 
created, which ultimately leads to implanting a patient tailored construct78.  
 
3.1.3: BIOREACTOR 
Bioreactors further the maturation of the tissue engineered scaffold, in the 
manner where they acclimate the construct in a simulated physiological 
environment79, such as pH, temperature, pressure, nutrient supply, and waste 
removal80.  Bioreactors are considered to have at least one of these five 
functions, (1) establish uniform cell distribution on a three-dimensional scaffold, 
(2) maintain the desired amount of gases and nutrients in the medium, (3) 
provide efficient mass transfer to the growing tissue, (4) expose developing 
construct to physical stimuli, and (5) provide information of the progress of the 
construct with in81. Once the chimeric construct, described previously described, 
is developed, the bioreactor will help with the first, second, and third functions, as  
Freed, et al. 81 delineated. Physical stimuli mentioned improve the structure and 
mechanical properties of the tissue engineered construct82,83. Specifically with 
the physical environment being stimulated, such as shear, tension, and 
compression84, cells that are seeded on to the heart valve, such as valvular 
endothelial cells, could mature and proliferate. This indication of movement of the 
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seeded cells is also an important aspect of recognizing that if cells could do that 
in a simulated environment the same could happen in an in vivo environment. 
Now, even though cell use, scaffold development, and design of bioreactors have 
been commonly studied, the method of seeding autologous cells has been an 
obstacle that has not yet been standardized nor perfected. Thusly, developments 
of instruments to create replicable results are being currently studied/  
 
3.2: CURRENT DEVELOPMENTS IN TISSUE ENGINEERING  
3.2.1: 3D BIOPRINTING 
 An innovation of three-dimensional (3D) printing has emerged, in the 
capacity which a combination of cells, growth factors, and biomaterials can now 
be used to print 3D structures85. 3D Bioprinting can now fabricate naturally 
imitating structures with several bioinks (composition of biological materials that 
can be extruded into filament “ink”) into a 3D structure, with crosslinking whether 
it be UV photo crosslinking or chemical crosslinking. The method of 3D printing 
can replicate designs to small tolerances (depending on the material being used) 
and creates porous structures for cells to migrate and communicate with each 
other. Due to the computerized nature of the printing, reproducibility, and 
increased manufacturing techniques which has been lacking in traditional tissue 
engineering methods. The commercialization of 3D bioprinters has also been a 
revolution for many niches, such as cardiovascular tissue engineering86. In 
42 
 
addition, the ability to include gel cell-vehicles has been a something that has 
piqued the interest of many researchers87-90. Furthermore, the concept of 
reproducibility and controlled manner of cell seeding led to the experimental 
design of whether it was better than the traditional manner of seeding for 






CHAPTER 2: PROJECT RATIONALE 
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AIM 1: CREATE THE FOUNDATIONAL CONSTRUCT FOR A TISSUE 
ENGINEERED PULMONARY VALVE 
SUB AIM 1: DIFFERENTIATE HUMAN ADIPOSE DERIVED STEM 
CELLS INTO ENDOTHELIAL-LIKE CELLS 
HYPOTHESIS: Human Adipose Derived stem cells can be differentiated 
into Endothelial-like cells with chemical and mechanical stimuli. 
APPROACH: Differentiation of ADSCs into ECs will occur when hADSCs 
were cultured with Endothelial Cell Growth Supplement (ECGS) media for 
up to 3 weeks on 0.1% gelatin coated flasks, then exposed to 
physiological shear (12 dynes up to 8 days)91. 
 
SUB AIM 2: DECELLULARIZE A PORCINE PULMONARY VALVE INTO 
AN ACELLULAR SCAFFOLD 
HYPOTHESIS: A porcine pulmonary valve can be decellularized through a 
perfusion system and a change of various solutions. 
APPROACH: Porcine pulmonary valves were obtained cleaned and 
thinned with a retention of ~5cm of pulmonary artery. Valves were placed 
into a metal mounting ring, with an acrylic ring and spring inside. The 
valves were placed into a perfusion system and kept at a differential 
pressure of 10mmHg (+/- 5 mmHg), with a cyclic regime of 3 minutes ON 
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and 30 seconds OFF. For 10 days, the valves were subjected to various 
solutions for the decellularization process. 
 
AIM 2: ASSESS THE RETENTION AND ADHESION OF ENDOTHELIAL-LIKE 
CELLS ON ACELLULAR VALVE SCAFFOLDS 
HYPOTHESIS: A 3D bioprinting seeding method for reendothelialization of an 
acellular scaffold will show improved coverage, adhesion and retention of cells as 
compared to the drop-wise seeding method.  
APPROACH: A pattern of rasterization for emulsion (cells suspended in fibrin) 
dispersal will be designed in the 3D bioprinter’s software. Scaffolds would be 
prepared into wells of a 6-well plate with a sterilized cotton ball prepared for 
further use. For 3D bioprinter cell seeding, the scaffold would be placed “upside-
down”, and the design would be printed, then cotton ball would be placed into the 
well and the scaffold would be flipped on to it, final print would happen. For the 
manually seeded approach, instead of bioprinting, a syringe would be used to 
manually drop-wise seed the scaffold. Several timepoints would be assessed to 
show adhesion and retention of cells on scaffold surface. At the time points 
seeded scaffold would be analyzed via PrestoBlue assay for quantitative cell 
count and Live/Dead for qualitative cell count. Similarly, all the scaffolds at the 
time points would be processed for histology with a follow up of 
immunohistochemistry to identify the expected presence of cell-cell attachment 
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and cell-extra cellular matrix attachment proteins and maintenance of endothelial 
markers. 
 
AIM 3: EVALUATE EFFECTS OF DYNAMIC CONDITIONING OF RE-
CELLULARIZED CONSTRUCTS IN A VALVULAR BIOREACTOR  
HYPOTHESIS: As the seeded construct is progressively conditioned within the 
valvular bioreactor, we expect to prove that seeded cells will maintain adherence, 
viability, and specific markers during the conditioning period.  
APPROACH: Constructs created in AIM 1 will be mounted in the heart valve 
bioreactor to expose the seeded scaffolds to physiological environments. The 
assessment of the adhesion and proliferation of cells will be assessed with the 
same methodology of AIM 1, as well by finding the expression of endothelial-like 
proteins and assessing the endothelial cell like functionality through specific 
assays.  
 
EXPECTATIONS AND IMPACT:  
By the completion of this project, we expect having developed a biologically 
defined biocompatible scaffold seeded with autologous cells, that is potentially 
capable of valve regeneration. The approaches and expected results of this 
project hold potential for the development of a leading-edge, patient tailored, and 
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SIGNIFICANCE      
 Cardiovascular disease (CVD) is the prime cause of death nationwide[9], 
taking an estimated 17.9 million lives each year[10]. It is speculated that by 2030, 
43.9% of the United States population will have some form of CVD26. Under the 
umbrella of CVD, more than five millions of Americans are diagnosed with heart 
valve disease (HVD) each year27,28. Although most of the population that suffers 
from HVD are the elderly, the population of growing children cannot receive the 
same treatment as their older counterparts. In the U.S., hospital costs for 
individuals with cardiovascular defects in 2013 were about $6.1 billion, where 
critical congenital heart defect associated hospitalizations had the highest mean 
and median cost of the birth defect categories considered ($79,011 and $29,886, 
respectively)29,92.  
Events which may lead children to have heart valve defects at birth, 
referred to as congenital heart defects (CHD), lead to extensive surgeries 
throughout the infant’s life.  The American Heart Association estimates that out of 
1,000 births at least eight babies will have some sort of CHD in the United 
States1,30.  
About one in every four babies born with a heart defect has a critical CHD, 
identified as heart defects that lead to low levels of oxygen in a newborn,  and 
will have an invasive intervention with in their first year of life32. The cost of 
identifying a newborn with critical CHD has been estimated at $20,862 per 
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newborn detected1 and hospitalizations with critical CHD account for 26.7% of all 
costs for CHD hospitalization92, where pediatric hospitalizations with CHDs 
accounted for approximately $5.6 billion in hospital costs, representing 15.1% of 
costs for all pediatric hospitalizations in 200929. 
A normal healthy heart is a muscular organ that sits in the chest, and is 
composed of four valves, two atriums and two ventricles (FIGURE 14). The 
function of the heart is to pump oxygenated blood to the entire body. Infants with 
CHD have an improper development of the heart which leads to low level of 
oxygen in the newborn. Some CHD can be diagnosed during pregnancy using a 
special type of ultrasound, called a fetal echocardiogram, which creates pictures 
of the heart of the developing baby. If the defects are not able to be identified 
during the pregnancy, they can be identified at birth or as the child ages. Low 
levels of oxygen detected with pulse oximetry are the primary identification of a 
potential CHD, such as pulmonary atresia (FIGURE 9: A4) hypoplastic left heart 
syndrome (FIGURE 9: B36), coarctation of the aorta (FIGURE 9: C33) , and 
tetralogy of Fallot (FIGURE 9: D34), detected.  
Hypoplastic left heart syndrome (FIGURE 9: B36), is the 
underdevelopment of the left side of the heart, which leads to interrupted blood 
flow in the heart, mixing the oxygenated and deoxygenated blood, resulting in 
low levels of oxygen of the infant. Another CHD is pulmonary atresia (FIGURE 9: 
A4), which is the lack of development of a pulmonary valve. The absence of the 
pulmonary valve disrupts the blood flow of the heart, especially before it is 
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oxygenated in the lungs. A complicated CHD that requires surgery is the 
Tetralogy of Fallot due to its complex defects. In the Tetralogy of Fallot (FIGURE 
9: D34) there are four defects in the heart which are: 1) A ventricular septal 
defect, 2) Narrowing of pulmonary valve and main pulmonary artery, also known 
as pulmonary stenosis, 3) Enlarged aortic valve and due to the ventricular septal 
defect, opens from both ventricles, and 4) Abnormal thickness of muscular wall of 
lower right ventricle, called ventricular hypertrophy. 
Treatments for CHD, such as tetralogy of Fallot, include the replacement 
or alteration of the pulmonary valve (PV), to ensure alleviation of symptoms. 
Follow up treatments occur as the child ages due to the lack of adaptability of the 
procedures, leading to a cost of $40,385 per life-year gained (2011 US dollars) 
until the age of 201. Current models for replacements, such as mechanical and 
biological, have limited life spans due to bleeding risk48 and degradation and/or 
calcification49, respectively and do not grow with the patient. Current treatments 
for CHD involving surgery or replacement of the PV. do not consider the 
children’s change in immunity nor size. An example of CHD is a child born with a 
defect in the RVOT, which is a functional unit in the heart that is located between 
the supraventricular crest and the PV, such defects include tetralogy of Fallot and 
pulmonary atresia50,51. The function of the RVOT is to carry blood from the right 
ventricle to the lungs, making the PV a paramount piece in the process. At the 
time of diagnosis of defect in the RVOT invasive surgery is imminent for the child, 
but current PV replacement options of xenografts, allografts, and mechanical 
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devices will typically fail and require another surgery52. Mechanical prosthesis 
have thromboembolic risk and lifetime of need for anticoagulants68, while 
xenografts and allograft used for right ventricular outflow tract reconstruction in 
children and young adults often degeneration and failure26. Degradation of 
biological grafts is due to the children’s high immunological competence52, while 
surgical approaches to reconstruct valves making use of auto or commercial 
available pericardium to augment defective cusps or fabricate mono cusps29 
have variable results, as it depends on 26,30,93, but most often fibrosis occurs68. 
Due to concerns of the lack of options for children with CHD tissue engineered 
constructs continue to be considered if it prevails it can also another approach for 
other patients. A tissue engineered pulmonary valve (TEPV) addresses the 
short comings of the current methods of valve replacement by creating a living 
PV. 
As per the notion of tissue engineering, the use of a scaffold, such as a 
decellularized porcine pulmonary valve, and autologous cells creates a living 
replacement for the organ. The identification of the scaffold, such as a porcine 
pulmonary valve, is essential to be comparable to its fresh counterpart. In 
addition, the decellularization process removes the potentially immune-rejective 
components, while keeping the structure of the organ. Following the preparation 
of the scaffold, autologous cells are embedded into the scaffold and the 
combined construct into a conditioning environment. The use of a natural scaffold 
may retain cues which could signal the patient’s own cells to repopulate the 
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scaffold. In addition, the construct might adapt to become the patient’s pulmonary 
valves and regenerate as the child grows. The regenerative properties of this 
method could ultimately eliminate the gap of treatment and the path the way to 
tailor treatments to the patients.  
 Concurrently, with the notion of the use of autologous cells the use of 
human adipose derived stem cells (hADSCs) as a cell source which are 
considered for the cell population in the tissue construct due to their various 
advantages of availability, isolation protocols, and multipotency. The readily 
availability of human adipose derived stem cells69,71 and “ability to isolate a 
consistently homogeneous population of undifferentiated adult stem cells from 
adipose tissue”72 as expressed by Aust, et al makes the source highly desirable. 
The cells are also multipotent71,73 as their differentiation properties allow the cells 
to follow the path of endothelial cells and smooth muscle cell. The endothelial cell 
differentiation, hADSCs are said to have a common progenitor that leads this 
differentiation74. The importance of differentiation of hADSCs into endothelial 
cells leads to the lining of the scaffold, which will a may ease coagulation and 
anticoagulation21 reaction, inflammation, and immune response21. 
The valvular engineering approach follows the tissue engineering 
paradigm in which autologous cells are isolated and cultured while 
simultaneously creating a scaffold, then creating a chimeric construct which can 
implanted into the patient, ultimately implanting the patient tailored construct75. 
The need of obtaining such construct is to create a lasting remedy for patients to 
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reduce the cost of constituent surgeries. We will keep the structural the unique 
micro- and macro- tissue architecture by creating an acellular scaffold with 
a pulmonary valve and reendothelialize with autologous cells. The following 
project will show a proof of concept with the use of adult pulmonary valve 
diameters, average of 23.9mm78, while children’s pulmonary valve diameters 
range from 9.2mm – 16.8mm depending on their age of 3 months to 10 years 
respectively94.  
Key features highlighting the significance of this project are: 
• The great clinical need for a pediatric focused alternative for pulmonary 
valve replacement. 
• The tissue paradigm of decellularized pulmonary valve and 






The novelties of the proposed project are the differentiation of hADSCs 
into ECs, the use of 3D bioprinting as a method of seeding, and the bioreactor 
conditioning of the seeded scaffold. The hADSC-derived ECs are determined by 
their expression of EC protein markers through several processes from culturing 
to seeding to conditioning on a scaffold. Although differentiation of hADSCs is not 
a new concept, their lasting differentiation has not been a focus for research. The 
aims proposed are designed to highlight the importance of the endothelialization 
of acellular scaffold and focus on the lasting differentiation properties of hADSCs. 
Endothelial cell properties and role has been studied at lengths, which will be 
considered in the definition of successful differentiated cells. The differentiation 
properties of the stem cells are acclaimed in the scientific realm, but their pliable 
nature leads to an unconsidered path of their properties as differentiated models. 
Under the proposed research methods, the properties of the hADSC-derived 
endothelial cells will be monitored within each step of the proposed aims to 
ascertain their expressed proteins and their functional role as endothelial cells. 
As the tissue engineering paradigm is used, the differentiated cells are to 
propagate as their original counterparts should. The use of 3D bioprinting with a 
fibrin-cell bioink as a seeding method is also a pioneering notion. The 
consideration of the addition of fibrin is for increased attachment of the cells onto 
the scaffold, especially when shear force is applied91,95. The added substrate can 
increase the retention, specifically within a shear stress environment. Following 
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the assessment of manual seeding method in contrast to a 3D bioprinting 
seeding, inclusion of bioprinting leads to more consistency and customizability.  
Furthermore, progressive bioreactor conditioning of seeded scaffold 
generates a living valve with hADSC-derived ECs. Introducing the seeded 
scaffold, cells which have been adapted to shear force, to physiological pressure 
may yield a living valve. Classifying the importance of the cell adhesion as a full 
aim will enable a focus of the adaptability of cells that are retained on the 
acellular construct. In addition, there is a consideration of accommodating the 
hADSC-derived endothelial cells in their conditioning of pseudo-physiological 
environment. Lastly, bioreactor studies with ramp up features of physiological 
system has been seen, but not assessed for already shear-conditioned cells.  
In summary, innovative features include: 
• The differentiation of hADSCs into endothelial-like cells via chemical and 
mechanical stimuli. 
• Endothelization seeding method with 3D bioprinted fibrin-cell bioink  





PART 3: APPROACH 
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AIM 1: CREATE THE FOUNDATIONAL CONSTRUCT FOR A TISSUE 
ENGINEERED PULMONARY VALVE 
SUB AIM 1: IN-VITRO DIFFERENTIATION OF HUMAN ADIPOSE 
DERIVED STEM CELLS (HADSCS) INTO ENDOTHELIAL CELLS VIA 
THE ADDITION OF ENDOTHELIAL CELL GROWTH SUPPLEMENT 
AND INDUCTION OF SHEAR 
METHOD 
STEP 1: CULTURE  
The differentiation method started with the preparation 0.1% gelatin 
solution96 for the pre-coating of the cell culture flasks with the solution via created 
via the ATCC protocol97. hADSCs (LaCell, USA) were cultured in Media 199 
(Sigma Aldrich, M2154), 13% Fetal Bovine Serum (Bio-techne), 
Antibiotic/Antimycotic 12mL/L(Corning), L-glutamine 0.1g/L (Fisher Scientific, 
BP379-100), and Heparin 7.5U/mL (Sigma Aldrich, H4784), for 8 days (+/- 3 
days). We added Endothelial Cell Growth Supplement (ECGS), 50μg/mL (EMD 
Millipore, 02-102) to the medium solution, hADSCs were to be expanded for 3 
weeks91. After the addition of ECGS to the medium, it was further referred to as 




STEP 2: SHEAR 
After the differentiation period, the hADSCs were transferred to 6-well 
plates (FIGURE 14) and kept in static conditions overnight. Static group 
continued to be incubated in same condition, while the shear group was placed 
on orbital shaker inside the incubator set to 200 RPM (12 dynes)98. Both groups 
grew for an additional 8 days, as per Fischer, et al91 and Dardik, et al98. 
Immunofluorescence (IF) was conducted to ascertain the presence of platelet 
endothelial cell adhesion molecules (CD31), von Willebrand factor (vWF), and 
endothelial nitric oxide synthase (eNOS). Additionally, Acetylated Low Density 
Lipoprotein (AcLDL) Uptake assay (ThermoFisher, L3484) was used for the 





Experimental groups assessed were: 
• Human umbilical vein endothelial cells (hUVECs), referred to as ECs were 
plated on a gelatin coated 6-well plates, with media described above 
without ECGS. ECs did not experience any shear stimuli. 
• Undifferentiated hADSCs, further referred to as UNDIFF, were plated on 
6-well plates without gelatin coating and were cultured with medium 
described above without ECGS and heparin. These cells did not 
experience any shear stimuli.  
• Differentiated hADSCs were plated on gelatin coated 6-well plates and 
cultured with ECGs media, one group experienced shear for 8 days (GEL 
SHEAR) and the other was in static conditions for 8 days (GEL STATIC). 
Figure 14: Visual representation of experimental set up and analysis of wells with their 




STEP 3: IMAGING 
Differentiated hADSCs and control groups, human umbilical vein 
endothelial cells (referred to as ECs) and undifferentiated hADSCs (referred to as 
UNDIFF), were imaged at various magnifications, 10X, 20X, and 40X analyzed 
via ImageJ’s color threshold where the area of the antibody presence (by color of 
fluorescence) was identified and normalized by the number of nuclei within the 
image. Examples of images and summary of the results are seen in the results. 
Several groups, specifically gelatin coated static differentiated hADSCs (GEL 
STAT) and gelatin coated shear differentiated hADSCs (GEL SHEAR), were 
analyzed and all images were compiled.  
 
STEP 4: IMAGE ANALYSIS 
All images were compared, regardless of magnification, which caused 
large standard deviations within groups. The area of the fluorescence was 
identified by splitting the images into their color channels (Red, blue, and green). 
An automatic threshold was applied to the channel of interest, red for AcLDL 
Uptake Assay and green for IF protein expression due to the use of 
ALEXAFLUOR 488, and by the area was measured using ImageJ. The 
“measuring” tool in ImageJ limited the area to the threshold region. A macro was 
used to apply the same steps to each image, the results of the area (µm2) and 
percentage of area of threshold per image was stored. If the percentage of area 
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of the threshold was above 50%, meaning fluorescence took up half of the image 
or more, the image was further scrutinized for accuracy. If an inaccuracy was 
identified due to the automatic threshold, the data was excluded. The nuclei of 
the cells were analyzed via the built-in plugin “Analyze Particle” in ImageJ with 
additional steps to clarify the edges of the nuclei. Steps prior to the use of the 
“Analyze Particle” were splitting images into the color channels (red, blue, green) 
and selecting the blue channel, due the blue fluorescence of DAPI, for further 
analysis. The blue channel which includes the DAPI stained nuclei, was made 
into a binary image and via the image process of “dilate” to soften the edges of 
the particles for ease of identification, and via the image process of “watershed” 
was used to segment particles that touched. Finally, the “Analyze Particle” plugin 
was used with the limitation of size of 50 µm2-1,000 µm2 to limit the inclusion of 
artifacts. A macro was created to include the images scale and steps were 
applied to all images. The data was normalized by the number of nuclei and 
expressed by the area of protein presence per nuclei of cells (µm2).  
 
RESULTS AND CONCLUSION OF PRELIMINARY SUB AIM 1:  
Images were taken to evaluate the AcLDL uptake assay, FIGURE 15 
shows representative fluorescent results for the all the groups: EC, GEL SHEAR, 





After analysis of the results of the AcLDL uptake there was no significant 
difference between the groups (FIGURE 16), although the differentiated hADSC 
in the GEL SHEAR group did show the highest red fluorescent intensity per 
nuclei.  
Figure 15: Fluorescence images of (A)ECs, (B)GEL SHEAR, (C)GEL STAT, and (D)UNDIFF. 




ECs expressed the highest intensity, with a statistical difference, of CD31, 
eNOS, and vWF compared to the other groups, GEL SHEAR, GEL STAT, and 
UNDIFF (FIGURE 18). When the experimental groups were compared to each 
other (FIGURE 18), there was a prevalence of higher protein expression in the 
GEL SHEAR group, with a significant difference in CD31, when compared to 
GEL STAT. Based on the data, UNDIFF group (FIGURE18) showed a decrease 
in expression of all proteins, and AcLDL. An example of representative IF images 
are seen in FIGURE 17. 
 
 
Figure 16: Graphical representation of red fluorescent pixels per nuclei. Quantitative 




Figure 17: Fluorescence images of endothelial cells (EC, A-C), differentiated hADSCs on a 
gelatin coated plate after 8 days of shear (GSH, D-F), and differentiated hADSCs on a gel 
coated plate in static conditions (GST, G-I). Green fluorescence identifies the presence of 






At the culmination of this study, endothelial cell proteins expression was 
seen in the experimental groups, supporting the generation of hADSC-derived 
endothelial-like cells. Furthermore, differentiated hADSCs up took AcLDL like 
their endothelial cell counterparts, further suggesting the similarity in endothelial 
functionality between the groups. Finally, the inclusion of shear during the 
differentiation process led to more fluorescence, thus increasing the likelihood of 
differentiated cells to express more endothelial cell properties. FIGURE 19 
summarizes the results of the fluorescence images and their analysis.  
 
Figure 18: Quantification of fluorescent pixels (which indicate protein presence) per nuclei 





SUB AIM 2: DETERMINATION OF ACELLULARITY OF 
DECELLULARIZED PULMONARY VALVE SCAFFOLDS THROUGH 
IMMERSION AND PERFUSION.  
METHOD: 
Two different methods of decellularization were assessed, immersion and 
perfusion. During immersion, cleaned and thinned PVs with 5cm< of pulmonary 
artery were immersed into various solutions while incubated in a constant state of 
motion. As per the perfusion protocol, valves were placed into metal mounting 
rings with acrylic rings and a spring inside.  
The mounted valves were then plugged in the pulmonary artery opening 
then placed into a valve decellularization system, keeping a pressure differential 
of 10mmHg +/- 5, in a cyclic regime of 3 minutes ON and 30 seconds OFF. Both 
decellularization protocols change through various solutions, such as 0.5M of 
FIGURE 19: Qualitative summary of presence of protein or uptake of AcLDL by each type of 
cell. If there was presence and/or uptake of AcLDL it is demonstrated by “+” If there is not a 
presence and/or uptake of AcLDL, then by “-“.Furthermore “+/-“ illustrates not a positive 
presence nor a negative presence of the protein.  
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sodium hydroxide (NaOH) [1 hour], detergent solution [4 days, with a change 
every two days], 0.02% sodium azide [Rinsing 1 day], DNase/RNase solution [2 
days], 70% ethanol [Rinsing overnight], and peracetic acid [2 hours]. The 
decellularization process using perfusion apparatus lasted 10 days. During the 
final stages of each method, peracetic acid was used to sterilize the acellular 
tissue. In the perfusion system extra steps were added to ensure full sterility of 
the PV root. For the sterilization of the perfusion system, peracetic acid was 
perfused through the system for an hour, following with the disassembly of the 
system and valve mounting, finally PVs were moved to a sterile container and 
sterility procedure continued until sterile storage. The acellular qualities of the 
scaffolds were determined through histology and DNA assays99 to ensure 
decellularization procedure by success criteria of (1) no nuclei visible through 
histology, via hematoxylin and eosin (H&E) and 4’,6-diamidino-2-phenylindole 
(DAPI), (2) the remaining double stranded DNA content did not exceed in 200 
base pair in length, and (3) the amount of DNA did not exceed 50ng per mg of 
dry weight of the acellular scaffold76,77.  
 
RESULTS AND CONCLUSION OF SUB AIM 2:  
The immersion method did not yield acceptable decellularization results 
(high residual DNA content, presence of cell nuclei, data not shown).  FIGURE 
18 shows the change in color of the pulmonary valves after the start of the 
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perfusion decellularization process (FIGURE 20 A), and towards the end of the 
decellularization process (FIGURE 20 B).  
 
Fresh porcine pulmonary valves were stained with H&E and DAPI at 
different positions such as the leaflet/cusp, the sinus pocket, the sinus muscle, 
and the proximal pulmonary artery (FIGURE 21). The decellularized PV was also 
stained at these positions and compared to the fresh PV.  
 
  
Figure 20: Images of perfusion decellularization process. A: Image of the pulmonary valves 
during the beginning process of decellularization, still pink in color. B: Images of the 
pulmonary valves close to the end of the decellularization, white in color indicating 






Figure 21: Location of dissection for the fresh and decellularized pulmonary valve to be 
compared to each other.    








Figure 22: Validation of Decellularization of the Pulmonary valve with H&E. A-D: Fresh PV 
tissue. Purple indicates the presence of nuclei. E & F: Decellularized PV tissue. No nuclei are 
seen in the images. All images are representative of the tissue collected.  
  
Figure 23: Validation of Decellularization of the PV with DAPI. A-D: Fresh PV tissue. 
Fluorescent blue indicates the presence of nuclei. E & F: Decellularized PV tissue. No nuclei 





The histology showed the high number of nuclei in the fresh tissue 
(FIGURE 22 & 23, A-D), which was mirrored by the gel-electrophoresis (FIGURE 
24, LEFT COLUMNS 2-6). The decellularized pulmonary valve, illustrated via 
DAPI and H&E, did not have nuclei in prominent regions of muscle and 
endothelial layer of the scaffold (FIGURE 22 & 23, E and F).  
 
 
Figure 24: Validation of Decellularization of the PV with Ethidium Bromide Agarose Gel 
Electrophoresis. All columns labeled with their respective sample, LEFT: Standard, MIDDLE: 
Fresh, and RIGHT: Decellularized Each decellularized location was sampled twice, thus 
each respective locations have two columns in the electrophoresis image. 
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Following histology, a gel electrophoresis using 1% agarose gel with 
ethidium bromide was conducted with fresh and decellularized samples in the 
same run. The gel electrophoresis (FIGURE 24) did not show any DNA based 
pairs within the dissected locations shown in FIGURE 21. Each region in the 
decellularized valve was ran via two samples, thus two columns, with no 
indication of DNA based pairs (FIGURE 24), while the fresh samples illustrated 
high DNA based pairs (FIGURE 24). 
 
Figure 25: Validation of Decellularization of the PV with DNA Quantification. Each region was 
denoted at the bottom of the graph: (LEFT to RIGHT) Leaflet, Sinus Pocket, Sinus Muscle, 
Proximal PV Artery, Muscle 1, and Muscle 2. All locations were compared to a fresh PV 





In addition, the DNA quantification of the decellularized pulmonary valve 
scaffold and its regions are significantly less that the fresh values (p-value all less 
than 0.00) (Graphical representation in FIGURE 25). In addition, all locations 
show that there is less than 50 ng of DNA per mg of weight of the tissue, more 
samples of decellularized PV muscle were taken and analyze to further prove the 
success of decellularization. While comparing the fresh tissue information in 
contrast with the decellularized scaffold information demonstrates a statistical 
significant difference (FIGURE 25), the decellularized information shows its 
satisfactory as an acellular scaffold under the prominent conditions within Crapo, 
et al.’s76 considerations. As the conclusion of the preliminary results, using the 
perfusion method for decellularization of PV is adequate to create an acellular 
scaffold for the replacement of PVs.  
 
CONCLUSION OF AIM 1: 
hADSCs showed EC markers after ECGS media was added and shear 
stress was induced. In addition, the differentiated hADSCs were able to uptake 
AcLDL like their endothelial cell counterparts. Finally, a porcine pulmonary valve 
can be decellularized in a perfusion system with several changes of solution. 
There were no visible nuclei in the histology (H&E and DAPI), no detectable DNA 
base pairs in the Ethidium Bromide Agarose Gel Electrophoresis, and less than 
50 ng of DNA per mg of sample. These are the successful definitions of a 
decellularized scaffold as per Badylak’s team76.Leading us to conclude that the 
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pulmonary valve was successfully decellularized, as any DNA remnants are 






AIM 2 APPROACH: WE WILL COMPARE THE EFFICACY OF TWO CELL 
SEEDING METHODS FOR RE-ENDOTHELIALIZATION OF ACELLULAR 
VALVES  
METHOD:  
Decellularized scaffolds from preliminary study will be fitted into 6-well 
plates where the valve sits directly into the well (FIGURE 27 B). Valve will be 
placed with ventricular side up and the design created using the CELLINK BIOX 
3D bioprinter (as shown in FIGURE 28) would be bio-printed onto the valve with 
fibrin-cell biological ink.  
 
PRIMARY BIOPRINTING SEEDING STUDY: STATIC CONDITIONS 
STEP 1: DEVELOPMENT OF DESIGN TO BE BIOPRINTED  
To use the CELLINK BIOX 3D bioprinter for seeding, a design for printing 
was developed. A simple design, shown in FIGURE 26 A, was designed via 
SolidWorks and was used for the future printing of the fibrin-cell gel construct. 
The manner of design was extrapolated from the use of the mounting rings which 
are used to place the valves in the bioreactor, and further verified by measuring 




The CELLINK BIOX 3D Bioprinter will print the above design in slices on 
decellularized pulmonary valves where the pulmonary artery has been resected 
for easier access of the printer’s nozzle onto the valve.  As the printer creates the 
design of the disk, the nozzle with the fibrin-cell ink will print at a 20.00mm/s and 
extrude at a pressure of 20kPa. The profile which the design will be printed is a 
hexagonal lattice with a honeycomb infill at a 75% density where the layer height 
will be 0.41mm. An example of the design that will be printed is in the figure 
above (FIGURE 26 C). The design is further printed into 6-well plates (FIGURE 
26 B). An example of the print is shown below, in FIGURE 27, as the CELLINK 
Figure 26: Design process of the bio-print. A: Design created in Solid Works, diameter of 28 
mm and depth of 1 mm, slices were then created to form 3 layers with Slic3r. B: Depiction of 
the prints that were going to be placed into a 6 well. C: Image of teach layer and the pattern 
in which each layer prints. First layer is on the left and with every added layer the density of 




BIOX 3D Bioprinter prints a design with CELLSTARTER ink before moving on to 
printing on the decellularized scaffold.  
 
 
STEP 2: PREPERATION OF THE GELMA FIBRIN BIOINK 
Prior to printing on decellularized scaffolds, the GelMA FIBRIN bioink was 
prepared as per CELLINK’s protocol.  In sterile conditions, the GelMA FIBRIN 
bioink cartridges were heated up to 37°C for 5 minutes until the bioink became 
liquid. Furthermore, differentiated hADSCs were passaged, counted, and then 
resuspended into 300µL of a cell suspension with ECGS media. At this point, 
CELLINK’s CELLMIXER kit was used with the components given, which were: 
1mL syringe, 12mL syringe, dispensing unit, mixing unit, extra bioink cartridge, 
female to female Luer lock adapter, and extra printing nozzles. The cell 




suspension was then withdrawn with a 1mL sterile syringe with 20 G needle (to 
avoid any more shear damage to the cells as they were going to be printed with a 
22 G nozzle). The syringe with cell suspension was placed aside. GelMA FIBRIN 
bioink, 3mL, was then transferred to a 12mL syringe, making sure the fibrin was 
still liquid. Then the dispensing unit was used by clipping the 1mL syringe with 
the cell suspension and 12mL syringe with the bioink, then connecting the 
dispensing unit with the mixing unit. The empty cartridge was then placed on the 
other side of the mixing unit then compressing the dispensing unit slowly, both 
syringe contents were mixed in the mixing unit and the mixture was contained in 
the extra bioink cartridge. At this point, the bioink is ready to be printed by the 3D 
printed as it will now be called fibrin-cell ink. 
 
 
STEP 3: PRINTING BIOLOGICAL INK ONTO DECELLULARIZED PULMONARY 
VALVES  
A sterile cotton ball was be placed into the well and the ventricular side 
(VS) of PV was be placed on it, in addition the leaflets were sutured together at 
the commissure to ensure no movement of the leaflets occurred nor any leakage 
of the fibrin-cell ink. With pulmonary artery side (PS) of the valve on top, the 
design was bioprinted, then a photo crosslinking occurred using the 3D Bioprinter 
365 nm UV module for 30 seconds. When the bioink was no longer fluid (usually 
within 5 – 10 seconds of printing). The same steps were taken with the manual 
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drop seeding but the bioprinted design was exchanged with a drop-wise seeding 
of a fibrin-cell emulsion. Ultimately two decellularized scaffolds were bioprinted, 
two others were manual seeded, and finally a fibrin-cell scaffold was printed. 
Finally, a 10 U/mL thrombin solution in ECGS media was placed into the wells, 
for further gelation and cleavage of fibrinogen into fibrin. FIIGURE 28 illustrates 
the manner in which the valves were placed in 6-well plates.  
 
Seeded scaffolds, shown above in FIGURE 26, were then be placed into a 
37oC incubator with 5% CO2 to allow for fibrin gelation and culture of cells. 
Seeded scaffold were left in static conditions, and analyzed after 24 HRS with 
PrestoBlue, then again after 96 HRS. After 4 days, the experiment was finalized 
and the scaffolds were examined through Live/Dead assay, and histology of 
DAPI and H&E.  
 
Figure 28: Experimentally seeded decellularized scaffolds in 6-well plates. Left plate, top: 
Scaffold were seeded with bioprinting protocol (BP). Left plate, bottom: Fibrin- embedded 




Results of Primary Bioprinting Seeding Study:  
After 24 HRs of seeding, PrestoBlue Assay was done to examine the 
retention of cells after the initial seeding occurred. This was done by removing 
the media in the wells and adding a mixture of 10% PrestoBlue (PB) with media. 
This solution was placed into the wells then the plates were placed into 37oC 
incubator with 5% CO2, and which were incubated for 10 minutes. After the 10 
minutes were up, the PB solution in each well was recovered and replaced with 
new media. The plates were placed back into the incubator for further cultivation 
of the seeded cells. The PB solution was distributed into an opaque black 96-well 
plate and then analyzed for fluorescence using a plate reader, which was set 




The results of the PB assay after 24 HRS are shown above (FIGURE 29), 
where a statistical difference in cell retention is seen between both seeding 
methods VS the Fibrin-Embedded Cell scaffold. Although there was no 
statistical difference between Manual Seeding and Bioprinted Seeding, there is 
a high number of cells counted for Bioprinted Seeding.  
 Another PrestoBlue assay analysis was done on the final time point of 
the experiment, which was 96 HRS/4 DAYS after initial seeding. PrestoBlue 
Figure 29: PrestoBlue results of cell retention after 24 HRs of seeding. There was a 
statistical difference found in the cell number between manual seeding and bioprinted 
scaffold (*) and bioprinted seeding and fibrin-embedded cell print (#), but there was no 
statistically significant difference between manual seeding and biopinting seeding, although 
more cell retention occurs in bioprinting seeding.  
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(FIGURE 30) results demonstrate that there is still a significant difference 
between the Manual Seeding and Bioprinted Seeding VS Fibrin-Embedded 
Cell scaffold. But in addition to that there was a significant difference in the 
number of cells between Manual Seeding and Bioprinted Seeding, 1.9X106 
cells VS 1.7 X106 cells, respectively.  
 
 In addition to PrestoBlue, the scaffolds were imaged with a stereo 
microscope without their sterile cotton ball to identify live cells on scaffolds using 
calcein. Each scaffold was then dissected into three parts, into their individual 
Figure 30: PrestoBlue results of cell retention after 96 HRs of seeding. There was a 
statistical difference found in the cell number between manual seeding and bioprinting 
seeding (%), manual seeding and fibrin-embedded cell print (*), and bioprinted seeding and 
fibrin-embedded cell print (#). 
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leaflets, and preserved in 10% formalin for further histological analysis such as 
DAPI and H&E.  
 
 
Calcein was used to detect where live cells were on the surface of the 
valves or fibrin-embedded cell print using a stereo scope. In the manual seeded 
scaffold (FIGURE 31 A and D), the cells were able to be seen on the edges of 
the fibrin scaffold. In addition, the fibrin gel was seen to have jagged edges off 
the scaffold (FIGURE 31 D). As far as the bioprinted scaffold, the cells were seen 
on the edges of the leaflets most pertinently (FIGURE 31 B and E), while the 
fibrin-embedded cell print did not have obvious cells inside (FIGURE 31 C and 
F).  
Figure 31: Live/Dead stereo scope images of the scaffolds after 4 days in static incubation. 
A&D: Manual Seeding, B&E: Bioprinting Seeding, C&F: Fibrin-embedded cell print. All are 





 In addition, the H&E showed that in both the manual seeded and 
bioprinted seeded scaffolds (FIGURE 32 A-C and D-F, respectively), cells were 
on the edges of the valve. As the cells that were seeded were differentiated 
hADSCs to endothelial-like cells, it demonstrates the beginning of re-
reendothelialization of the leaflets of the decellularized PV. In the fibrin-
embedded cell print (FIGURE 32 G-I), it was seen as a condensed gel with 
intermittent pores, but no prominent cells were seen.   
Figure 32: H&E of scaffolds, 4 days after seeding with manual seeding (A-C), bioprinting 




SECONDARY BIOPRINTING SEEDING STUDY: DYNAMIC CONDITIONS 
STEP 1: PRINTING BIOLOGICAL INK ONTO DECELLULARIZED PULMONARY 
VALVES  
The design was used from previous study was used, as well as the 
method of preparing the fibrin-cell bioink. In contrast from previous procedure, 
valves were mounted on polymer rings designed to fit into a rotator cup.  
 
 Prior to bioprinting seeding a method of step-by-step printing was 
established (FIGURE 33 TOP) and an example was created to verify that prints 
would stay on their respective side (FIGURE 33 BOTTOM). A sterile cotton ball 
Figure 33: Depiction of bioprinting process. TOP- Step 1: Sterile cotton placed on ventricular 
side of PV and flip. Step 2:  Print on pulmonary artery side of PV and flip. Step 3: Remove 
sterile cotton from PV and print again. BOTTOM- Example of how the fibrin gel stays on the 
area it was printed.  
87 
 
was placed under the ventricular side of the PV and leaflets were sutured 
together. Afterwards, the mounted valve (pulmonary artery side up) was placed 
into a glass petri dish for bioprinting to occur. Then bioprinter the deposited 
emulsion in the manner described in STEP 2 of previous study and then the gel 
was photos crosslinked for 30 seconds using the 365 nm UV module. Following 
that, using sterile forceps, the mounted valve (now with fibrin-embedded cell gel 
on top) was placed upside down in the petri dish and the sterile cotton that was 
placed in the ventricular side of the valve was removed. The design created for 
the study was printed again, now on the ventricular side of the mounted valve, 
and photo crosslinked for 30 seconds using the 365 nm UV module. During each 
pause of the bioprinter, a picture was taken with the valve in the petri dish before 
printing (FIGURE 34 A), after pulmonary artery side print (FIGURE 34 B), and 
after ventricular side print (FIGURE 34 C).   
 
Figure 34: Images of bioprinting process. A: Prior to any bioprinting, B: During bioprinting on 
the Pulmonary Artery side of the PV. C: During final print, on the Ventricular Side of the PV.  
Blue emulsion is the fibrin-cell bioink 
A B C 
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 When the bioprinting was completed on both sides of the decellularized 
scaffold, the mounted valves were then placed in rotator cups (FIGURE 35: A) 
with media containing 10 U/mL thrombin solution. Two filters were then placed on 
the lid of the rotator cups, to allow for gas exchange. Finally, the rotator cups 
were placed on to the rotator device (FIGURE 35: B) and set to 1 RPM, 
counterclockwise rotation. 
 
 After 24 HRS and 48 HRS the valves were analyzed with PrestoBlue, and 
the experiment was finalized. The valves were processed for Live/Dead imaging, 
then placed in formalin for further histological study. 
 
  
Figure 35: Images of valves in the rotator. A) Bottom view of the rotator cups. Movement at 1 
RPM, Counterclockwise rotation. B) Top view of the valves in the rotator cup. Movement at 1 
RPM, Counterclockwise rotation. 
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Results of Secondary Bioprinting Seeding Study:  
PrestoBlue analysis was done at 24HRs on both valves (n=2) and 48HRs 
(n=2) on the same valves as before after seeding and placing the valves in the 
rotator. It should be noted, at the time of stop (48HRS) there was some indication 
of contamination, thus prior to proceeding the valves were rinsed twice in sterile 
DPBS. FIGURE 36 illustrates the results between the time periods, where there 
was a significant increase after the 48Hrs of being in the rotator.  
 
 
 In addition to PrestoBlue, both valves were imaged after being incubated 
with calcein. FIGURE 37 illustrates the cell distribution among the valves. 
Figure 36: PrestoBlue Results between 24 HRS in rotator and 48HRs in rotator, significant 
difference between the time points. Indicated by * 
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FIGURE 37 A and B shows cells around the leaflets, which FIGURE 37 C shows 
cells made it to the rim of the valve, a speculation might be that it was the result 
of migration which will further studied in a longer study.  
 
Figure 37: Live images of valves with 
bioprinted seeding after 48Hrs of incubation 
in the rotator.  
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The DAPI illustrated (FIGURE 38) cell accumulation at the edges of the 
decellularized PV, leading to the thought of successful reendothelialization of the 
PV leaflets.  




RESULTS AND CONCLUSION OF AIM 2:  
 After the primary seeding study, it was seen that cell attachment to the 
scaffold was successful. Even though manual seeding showed a significant 
increase of cells, bioprinting was further analyzed due to its reproducibility. In the 
secondary seeding study, bioprinting seeding was successful in cell attachment, 
not only 24HRs after seeding but also after 48HRs. This may have been 
contributed to the dynamic nature of rotation, as it allows media movement 
through and around the valve. Due to the high number of cell attachment seen in 
PrestoBlue and positive results seen of cell attachment not only on the surface of 
the valve (seen through the LIVE imaging, FIGURE 37) but transactionally (seen 
through the DAPI, FIGURE 38, the next step is to follow the construct and 
seeding in a bioreactor with physiological pressures.   
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AIM 3: WE WILL CONDITION THE SEEDED SCAFFOLD IN PHYSIOLOGICAL 
PRESSURES USING A VALVE BIOREACTOR.  
RATIONALE:  
The use of valvular bioreactor on a decellularize PV seeded with hADSC-
derived endothelial cells will condition the construct. Furthermore, the 
conditioned construct within the bioreactor will be a proof of concept that the 
TEPV would be viable as a PV replacement. In addition, the use of the heart 
valve bioreactor will increase the understanding of changes that the environment 
induces onto the TEPV. Finally, using the valve bioreactor will produce additional 
insight into potential retention and proliferation of cells seeded in the prior aim. 
 
METHODS:  
STEP 1: Seeding and introduction to dynamic conditions 
When decellularized PV were seeded with hADSC-derived endothelial 
cells as the bioprinting seeding method in the previous experiment described. 
Both valves were seeded then an analysis of PrestoBlue was done on both 
valves for cell counting. Furthermore, after the analysis, the valves were placed 
into individual rotator cups and then filled with media (DMEM, 10% FBS, 1% 
Ab/Am) and placed into a 37oC incubator with 5% CO2. The rotator was then set 




STEP 2: Heart Valve Bioreactor conditioning with pulmonic pressures. 
 
To achieve the ramp-up suggested in the proposal (FIGURE 39), one 
valve was taken to be placed into the Heart Valve Bioreactor (FIGURE 40). The 
rotator cup valve was then considered the control, and the valve in the bioreactor 
was considered the experimental valve.  




Once the valve was mounted into the bioreactor, the bioreactor was then 
filled with media (DMEM, 10% FBS, 1% Ab/Am) and placed into a 37oC incubator 
with 5% CO2. The PV which was placed into the bioreactor was set to experience 
10 mmHg at systolic to 5 mmHg at systolic for 7 days (FIGURE 41 A). Top view 
of the pulmonary valve in Heart Valve bioreactor in FIGURE 41 B. 
  





Following the 7th day, both valves were analyzed with PrestoBlue and 
Live/Dead. Histology for H&E, DAPI, and Masson’s Trichrome was also done to 
assess the location of cells and location of fibrin get. In addition, 
immunohistochemistry was done on slides to assess if the endothelial properties 
of the differentiated cells were still present.  
 
RESULTS AND CONCLUSION OF AIM 3:  
 PrestoBlue analysis was done on one valve after seeding, then after 7 
days, each valve was analyzed in their respective conditions i.e., bioreactor and 
rotator. FIGURE 42 illustrates the cell numbers captivated by the PrestoBlue 
analysis. Although it shows there was a significant decrease in cell numbers 
between the seeding (n=1) and 7-day conditions (marked by * and $), the valve 
Figure 41: A) APTUS BIOREACTOR software for heart valve bioreactor, setting of 10 mmHg 
systolic pressure and 5mmHg diastolic with 8mmHg differential pressure. B) Image of seeded 
PV scaffold in the heart valve bioreactor.  
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exposed to physiological conditions in the bioreactor (n=1) retained a statistically 
significant higher number of cells than the valve in the rotator (n=1), denoted by # 
in FIGURE 42.   
 
 In addition, at the time of disassembly, at 7 days, the valves were imaged 




Figure 42: PrestoBlue analysis done after seeding with the bioprinted and then 7 days under 
bioreactor conditions and rotator conditions. There was a statistically significant decrease in 
cell number between seeding and the respective conditions, annotated as (*) for bioreactor 
and ($) for rotator. But ultimately the bioreactor valve had statistically significant higher cell 




Figure 43: Live imaging of bioreactor valve (A, C, E, G, and I) and the rotator valve (B, D, F, 
H, J) after 7 days in respective conditions. 
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 In FIGURE 43 both valves show a lot of cell attachment on the surface. In 
addition, there were cells close to the bottom of sinus of the valve, which was in 
the bioreaction, seen in FIGURE 43 I. Each valve was imaged on their pulmonary 
artery side (FIGURE 43 A-F) and ventricular side (FIGURE 43 G-I). Although the 
Rotator Valve seemed to have more cells, the macroscopic image of the valve 
(FIGURE 44) depicted the fibrin-cell gel intact, which after handling fell off. 
Images of the fibrin-cell gel that did not fully adhere to the valve, which was 
further imaged with DAPI (FIGURE 45, D-E). There was no fibrin-cell gel 
substance seen in the bioreactor valve (not pictured).  
 





 DAPI imaging of the bioreactor valve (FIGURE 45 A-C) showed cellular 
attachment to the endothelial sides of the valve. FIGURE 45 A shows attachment 
of cells on both side of the leaflet. In contrast, there was no continuous cell 
attachment on the rotator valve (FIGURE 45 G-I) and the fibrin from the rotator 
valve seems to still have cells with in (FIGURE 45 D-F). These images lead us to 
believe that the PrestoBlue results of the rotator valve, although their potential 
accuracy, overestimated the cell numbers on the valve itself.  





 Finally, the H&E results show there are cells on the endothelial layer of the 
Bioreactor Valve (FIGURE 46 A-C) and even though similar results seem to be 
true for the Rotator Valve (FIGURE 46 D-F), it is not discernable whether the 
fibrin has allowed for cells to attach to the valve or if it is the substance attached 
to the valve.  
 In conclusion, AIM 3 was successful in demonstrating that bioprinting a 
fibrin-cell gel on valves and conditioning them in dynamic environments keep 
cells viable and the fibrin-cell gel keeps the cells on the endothelial side of the 
valves. In the Bioreactor Valve, the fibrin-gel was no longer detectable leading to 
the conclusion the cells attached to the decellularized valve. In contrast, the 
Rotator Valve had obvious signs of the fibrin-gel on the surface with a lot of cells 
inside. This leads us to believe that although the delivery vehicle works, in the 
rotator the dynamic conditions for 7 days was not able to degrade it, thus no 
Figure 46: H&E of Bioreactor valve (A-C) and Rotator valve (D-F) 
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conclusion can be made on whether the cell attachment occurred on the 
decellularized scaffold in the rotator. 
 
Final Discussion:  
  
 Overall AIM 1 and AIM 2 were successful in their findings. In AIM 1, we 
were able to find characteristics that apply to endothelial cells after differentiating 
hADSCs both with ECGS and furthermore with induced shear. In addition to AIM 
1, porcine valves were successfully decellularized and able to be used as 
acellular scaffold for the continuation of the TEP. AIM 2 was able to show us the 
difference between manual seeding and bioprinting on a scaffold and bioprinting 
the scaffold. Although the 3-D printed scaffold by itself did not yield desirable 
results, it strengthens the belief that some other type of scaffold (decellularized 
PV) was necessary for this junction. In addition, manual seeding and bioprinting 
seeding did not show a significant difference in the cell number, but the 
reproducibility of bioprinting outweighed the manual seeding. Finally AIM 3 
demonstrated that dynamic conditions lead to further cell attachment. Particularly 
the valve that was placed into the bioreactor showed that the fibrin-gel delivery 
system was successful and its deterioration after the 7 days gives one hope that 
the cells have attached and can proliferate with more time.  
 For further directions on the project, the cell-scaffold construct would have 
to be evaluated for longer periods of time. In addition, if this project is used as a 
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proof of concept for TEHV for congenital heart defects, next step would be to 
downsize the valve. In addition to using a smaller valve, preferably a fetal heart 
valve, an animal study would have to be considered. For example, if a fetal 
bovine heart is dissected and the pulmonary valve was acquired, after the 
decellularization another animal models (such as sheep) cells would be seeded 
and then the construct conditioned. After successful conditioning, the newly 
seeded and dynamically conditioned fetal construct could be implanted into the 
sheep. This would assess whether the TEHV would truly adapt to the animal 
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